Prime and Magellan Rx present at: AMCP Nexus 2023

Event/registration: AMCP Nexus 2023

Medically Integrated Dispensing Services: Creative Value for Payers and Providers

Date/time: Tuesday, October 17, 7:30-8:45 a.m. Central

Prime participants: Ben Urick, Health Outcomes Research Principal, Prime Therapeutics; Kyle Verley, Director of Network Management, Prime Therapeutics

Rare Disease Spotlight: Hereditary Angioedema Treatment Advances, Patient Value, and Access to Care

Tuesday, October 17, 7:30 – 8:45 a.m. Central

Prime Participants: Sneha Sharma, Director, Medical Pharmacy Strategy, MRx

Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden

Date/time: Tuesday, October 17, 10:30-12:30 p.m. Central

Prime participants: YuQian Liu, Senior Director, Clinical Account Services, Magellan Rx

Managed Care Oncology Perspectives: CAR T-cells vs BiTEs

Date/time: Tuesday, October 17, 2:15-3:30 p.m. Central

Prime participants: Michelle Pannone-Booth, Senior Director, Account Services, Magellan Rx; Simone Ndujiuba, Product Development, Director of Clinical Oncology, Magellan Rx

Award-winning Research Supporting the Managed Care Pharmacy Agenda

Date/time: Tuesday, October 17, 2:15-3:30 p.m. Central

Prime participants: Nicholas Friedlander, Clinical Program Pharmacist, Prime Therapeutics

Biosimilar Operational Readiness: Managed Care Stakeholder Response to Market Expansion Impact

Date/time: Wednesday, October 18, 8:45 a.m.-10-:00 a.m. Central

Prime participants: Prerak Parikh, Director, Medical Pharmacy Strategy, Magellan Rx

Navigating NASH: A Discussion on Clinical Background, Patient Advocacy and Managed Care Considerations

Date/time: Wednesday, October 18, 8:45-10:00 a.m. Central

Prime participants: Brian MacDonald, Senior Director, Clinical Project and Program Management, Magellan Rx

Gene Therapies: Forecasting Potential Candidates Using Medical Pharmacy Claims Data

Date/time: Wednesday, October 18, 3:30-4:45 p.m. Central

Prime participants: Pat Gleason, AVP of Health Outcomes, Prime Therapeutics

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Events

October 14, 2024

Prime presents at: AMCP Nexus 2024

Annual conference gathers 2,500+ managed care leaders to discuss complex health care issues.

Events

September 16, 2024

Prime presents: Specialty Summit 2024

From Sept. 16–18, 2024, the 21st annual event will connect, elevate and transform relationships, with exceptional speakers, insightful panels and in-person networking, helping to build the future of specialty.

Events

September 11, 2024

Prime presents at: “GLP-1 Agonists + Food is Medicine: A New Recipe for Success in Treating Obesity? A Briefing for Congress”

Event on Sept. 11 in Washington D.C. will feature the latest information on using GLP-1s to tackle the obesity epidemic.

View all news